Results 1 to 10 of about 362,880 (295)
Treatment of chronic pain associated with nocturnal bruxism with botulinum toxin. A prospective and randomized clinical study [PDF]
Journal of Clinical and Experimental Dentistry, 2017 To evaluate the role of botulinum toxin type A (BTX-A) in the treatment of pain associated with nocturnal bruxism. Fifty subjects reporting nocturnal bruxism were recruited for a randomized clinical trial. Twenty five bruxers were injected with botulinum
Al Wayli, Hessa
core +2 more sources
Botulinum toxin A for the Treatment of Overactive Bladder
Toxins, 2016 The standard treatment for overactive bladder starts with patient education and behavior therapies, followed by antimuscarinic agents. For patients with urgency urinary incontinence refractory to antimuscarinic therapy, currently both American Urological
Po-Fan Hsieh +4 more
doaj +2 more sources
Toxins, 2023 In this randomized, double-blind, placebo-controlled study, we evaluated the efficacy of an individualized technique of subcutaneous injection of botulinum toxin type A (BoNT-A) targeted (SjBoT) to the occipital or trigeminal skin area in non-responder ...
Francesco Bono +9 more
doaj +1 more source
Botulinum Toxin: An Update on Pharmacology and Newer Products in Development
Toxins, 2021 Since its introduction as a treatment for strabismus, botulinum toxin (BoNT) has had a phenomenal journey and is now recommended as first-line treatment for focal dystonia, despite short-term clinical benefits and the risks of adverse effects.
S. Choudhury +3 more
semanticscholar +1 more source
Неврология, нейропсихиатрия, психосоматика, 2022 Parkinson’s disease (PD) is a multifactorial neurodegenerative disease. Consequently, there has been growing interest in identifying early preclinical disease symptoms and searching for their laboratory markers in recent decades.Objective: to studythe ...
D. A. Novotnyy +8 more
doaj +1 more source
Botulinum Toxin in Movement Disorders: An Update
Toxins, 2021 Since its initial approval in 1989 by the US Food and Drug Administration for the treatment of blepharospasm and other facial spasms, botulinum toxin (BoNT) has evolved into a therapeutic modality for a variety of neurological and non-neurological ...
Charenya Anandan, J. Jankovic
semanticscholar +1 more source
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A
Drugs, 2021 Botulinum toxin type A (BoNTA) products are widely used for therapeutic and aesthetic indications, but there is a need for longer-lasting treatments that maintain symptom relief between injections and reduce the frequency of re-treatment ...
N. Solish +5 more
semanticscholar +1 more source
Rehabilitation approaches in cervical dystonia
Неврология, нейропсихиатрия, психосоматика, 2021 Cervical dystonia (CD) is a form of focal muscular dystonia. The pathophysiology of CD includes central and peripheral sensorimotor mechanisms that lead to a pathological posture, imbalance, gait disturbances, and pain.
Z. A. Zalyalova, E. R. Iusupova
doaj +1 more source
Неврология, нейропсихиатрия, психосоматика, 2021 Blepharospasm (BPS) is a variant of focal dystonia manifested by involuntary eyelid spasms with eye closure and/or increased spontaneous blinking. Along with motor symptoms, this condition is characterized by sensory, affective, and cognitive disorders ...
Z. A. Zalyalova
doaj +1 more source
Botulinum toxin preparations: areas for improvement and issues of standardisation
Биопрепараты: Профилактика, диагностика, лечение, 2023 Scientific relevance. Botulinum toxin preparations are a good example of using a deadly toxin as a unique therapeutic agent. However, there are many unresolved issues related to biotechnology, biological activity, interchangeability, and standardisation ...
M. V. Savkina +4 more
doaj +1 more source